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Abstract
Angiotensin-converting enzyme (ACE) inhibitors represent the fifth most often prescribed drugs. ACE inhibitors decrease 5-
year mortality by approximately one-fifth in cardiovascular patients. Surprisingly, there are reports dating back to 1979
suggesting the existence of endogenous ACE inhibitors, which endogenous inhibitory effects are much less characterized
than that for the clinically administered ACE inhibitors. Here we aimed to investigate this endogenous ACE inhibition in
human sera. It was hypothesized that ACE activity is masked by an endogenous inhibitor, which dissociates from the ACE
when its concentration decreases upon dilution. ACE activity was measured by FAPGG hydrolysis first. The specific (dilution
corrected) enzyme activities significantly increased by dilution of human serum samples (23.260.7 U/L at 4-fold dilution,
51.460.3 U/L at 32-fold dilution, n= 3, p= 0.001), suggesting the presence of an endogenous inhibitor. In accordance,
specific enzyme activities did not changed by dilution when purified renal ACE was used, where no endogenous inhibitor
was present (6556145 U/L, 605642 U/L, n= 3, p= 0.715, respectively). FAPGG conversion strongly correlated with
angiotensin I conversion suggesting that this feature is not related to the artificial substrate. Serum samples were ultra-
filtered to separate ACE (MW: 180 kDa) and the hypothesized inhibitor. Filtering through 50 kDa filters was without effect,
while filtering through 100 kDa filters eliminated the inhibiting factor (ACE activity after ,100 kDa filtering: 56.462.4 U/L,
n= 4, control: 26.460.7 U/L, n= 4, p,0.001). Lineweaver-Burk plot indicated non-competitive inhibition of ACE by this
endogenous factor. The endogenous inhibitor had higher potency on the C-terminal active site than N-terminal active site
of ACE. Finally, this endogenous ACE inhibition was also present in mouse, donkey, goat, bovine sera besides men
(increasing of specific ACE activity from 4-fold to 32-fold dilution: 2.8-fold, 1.7-fold, 1.5-fold, 1.8-fold, 2.6-fold, respectively).
We report here the existence of an evolutionary conserved mechanism suppressing circulating ACE activity, in vivo, similarly
to ACE inhibitory drugs.
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Introduction
Angiotensin-converting enzyme (ACE) is a member of the
renin-angiotensin-aldosterone system (RAAS), which is an impor-
tant regulator of blood pressure and salt-water homeostasis [1]. It
is a zinc-metalloendodipeptidase with two catalytically active sites
(N- and C-terminal catalytic domains). ACE catalyzes the
conversion of angiotensin I to angiotensin II, and the metabolism
of other peptides such as bradykinin [2].
ACE inhibitor drugs are the fifth most frequently prescribed
drugs [3], there were 162.8 million ACE inhibitor prescriptions in
2009 in the United States of America alone [3]. Their effectiveness
has been demonstrated by several large clinical trials: ACE
inhibitors reduce the risk of cardiovascular death, nonfatal
myocardial infarction or cardiac arrest in stable coronary heart
disease [4], improve the prognosis [5] and reduce the 5-week
mortality after myocardial infarction [6], reduce heart failure
mortality [7], inhibit left ventricular remodeling [8], delay the
manifestation of hypertension [9], and reduce the left ventricular
mass index in left ventricular hypertrophy [10], the incidence of
microalbuminuria and the risk of diabetic nephropathy in type 2
diabetes [11] and the likelihood of newly diagnosed diabetes
mellitus [12]. The latest therapeutic guidelines have incorporated
all these features [13–18]NNN, and ACE inhibitors are considered to
be an important component of the polypill proposed as a means of
reducing cardiovascular disease by 80% [19].
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Interestingly, there are several reports suggesting the existence
of endogenous ACE inhibitors dating back to 1979. It has been
reported that human serum albumin [20] and small (,10 kDa)
molecules [21] can inhibit ACE. Several more inhibitors has been
suggested afterward. These included substrate analogues [22,23]
and various other proteins [24,25]. Consequently efforts were
made to isolate and identify inhibitory molecules associating with
ACE in the rat lung [26] or in human sera [27], but these efforts
were overshadowed by the profound clinical success of ACE
inhibitory medication.
The goal of this present work was to study endogenous ACE
inhibition in human sera. It was found that the circulating ACE is
substantially inhibited by a non-competitive endogenous inhibitor.
Our data suggest that circulating ACE activity is regulated in vivo,
an effect which is similar to ACE inhibitory medication in
cardiovascular disease.
Methods
Ethical approval
All of the studies were approved by the Regional and
Institutional Ethics Committee, Medical and Health Science
Center, University of Debrecen, (UDMHSC REC/IEC number:
2894-2008) and by the Medical Research Council of Hungary. All
of the patients involved gave their written informed consent.
Patient’s blood sample collection, serum isolation
Blood samples were collected from volunteers by using a
standard aseptic technique. Native blood was incubated for
60 minutes at room temperature; serum fractions (separated by
centrifugation at 1,500 g for 15 min) were stored at 220uC until
further experiments.
ACE activity measurement using spectrophotometric
assay
ACE activity was measured as described by Beneteau et al. [28].
In brief, ACE activity was determined with an artificial substrate
(FAPGG, (N-[3-(2-furyl)acryloyl]-L-phenylalanylglycylglycine; Sig-
ma-Aldrich) in a reaction mixture containing 25 mM HEPES (N-
2-hydroxyethylpiperazine-N-2-ethanesulfonic acid), 0.5 mM
FAPGG, 300 mM NaCl, and the desired dilution of serum, at
pH 8.2. Measurements were performed in 96-well plates (Greiner-
Bio One) at 37uC. Changes in optical density (340 nm) were
measured at 5-min intervals for at least 90 min with a plate reader
(NovoStar plate reader; BMG Labtech). Optical density values
were plotted as a function of reaction time and fitted by linear
regression (GraphPad Prism 5.0). The fit and the data were
accepted when r2 was .0.90. ACE activity was calculated via the
equation:
activity~{ S=kð Þ D,
where S is the rate of observed decrease in optical density (1/min),
k is the change in optical density upon the complete cleavage of
1 mmol of FAPGG, and D is the dilution of the serum. ACE
activity is given in units where 1 U is equivalent to the cleavage of
1 mmol of FAPGG in 1 min.
Figure 1. Endogenous inhibitor masks ACE activity in human sera. Effects of dilution on the ACE activity were tested on purified renal ACE
(Purified ACE) and human serum (A). Plots were fitted by means of linear regressions in case of purified ACE while nonlinear regression was used in
case of serum ACE (indicated by the solid lines), while symbols denote the means 6 SEM of at least 3 independent determinations. The increase of
specific serum ACE activity (2.78-fold) upon dilution is also indicated. The hypothesis proposed to explain these findings is that an endogenous
inhibitor is present in the sera, which inhibits ACE at low dilution and then dissociates at higher dilution, unmasking ACE activity (B).
doi:10.1371/journal.pone.0087843.g001
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Measurement of domain specific ACE activity
Domain specific ACE activity was measured as described by
Carmona et al. [29]. In brief, quenched fluorescent peptide
substrates were used. Abz-SDK(Dnp)P-OH (Sigma-Aldrich) is
highly specific for N domain active site, Abz-LFK(Dnp)-OH
(Sigma-Aldrich) for C domain active site and Abz-FRK(Dnp)P-
OH (Sigma-Aldrich) can be cleaved by both active sites. The
reaction mixtures contained 100 mM tris(hydroxymethyl)amino-
methane hydrochloride (TRIS HCl, Sigma-Aldrich), 50 mM
NaCl, 10 mM ZnCl2 and 40 mM Abz-SDK(Dnp)P-OH or
50 mM Abz-LFK(Dnp)-OH or 10 mM Abz-FRK(Dnp)P-OH
fluorescent substrate, and the serum samples, at pH 7.0.
Measurements were performed in black, 96-well plates (Greiner-
Bio One) at 37uC, lex was 340 nm, lem was 405 nm. Changes in
fluorescence intensities were measured at 4-min intervals in case of
domain specific substrates for at least 90 min, and at 1.5-min
intervals in case of Abz-FRK(Dnp)P-OH substrate for at least
30 min with a plate reader (NovoStar plate reader; BMG
Labtech). Fluorescence intensity values were plotted as a function
of reaction time and fitted by a linear regression (GraphPad Prism
5.0). The fit and the data were accepted when r2 was .0.95. ACE
activity was calculated via the equation:
activity~ S=kð Þ D,
where S is the rate of observed increase in fluorescence intensity
(1/min), k is the change in fluorescence intensity upon the
complete cleavage of 1 mmol of fluorescent substrate, and D is the
dilution of the sample. ACE activity is given in units where 1 U is
equivalent to the cleavage of 1 mmol of fluorescent substrate in
1 min.
Direct measurement of ACE-catalyzed angiotensin I
conversion
Serum samples containing 0.5 mM angiotensin I (GenScript)
and 300 mM NaCl in 25 mM HEPES buffer, pH 8.20 were
incubated at 37uC. 5 mM EDTA was added to stop the reaction.
Angiotensin peptides were measured after filtering through a filter
with a 10 kDa pore size (Vivaspin, Sartorius Stedim Biotech).
HPLC analysis was performed with a HPLC technique on a
reverse-phase C18 column (Hypersil Gold, Thermo Scientific).
Eluent A was 0.01% aqueous trifluoroacetic acid (TFA, Sigma-
Aldrich), while eluent B was 0.01% TFA in acetonitrile (Sigma-
Aldrich). Angiotensin peptides were separated by using an elution
profile with a gradient from 22% acetonitrile to 55% acetonitrile.
They were detected by a diode array detector at 230 nm and the
area under the curve of each angiotensin peptide peek was
compared with calibration curves recorded when the purified
peptide was tested. The amounts of angiotensin peptides were
plotted against the reaction time and fitted by linear regression.
The kinetics of angiotensin I conversion was multiplied by the
dilution of the sera and given in mmol angiotensin I cleavage in 1 L
of serum in 1 min.
Fractionation of human sera
Serum samples from a healthy volunteer were ultrafiltered
through ultrafiltration devices with a pore size of 50 or 100 kDa
(Vivaspin 500, Sartorius Stedim Biotech) at 4uC for 6 min at
15,000 g. One volume of initial serum sample was diluted to 250-
fold in 25 mM HEPES, pH 8.2 (yielding 250 volume of diluted
serum sample). Then diluted serum samples were ultrafiltered until
the retained volumes reached the initial volumes of the serum
samples (1 volume). ACE concentrations of an initial serum sample
Figure 2. FAPGG hydrolysis proportional to angiotensin I
conversion. A representative ACE activity measurement is shown in A.
Decomposition of FAPGG results in a decrease in optical density at
340 nm. The decreases in optical density were plotted as a function of
the reaction time and fitted by linear regression. The kinetics of
decomposition was followed for at least 90 min. The slope of the linear
regression was taken as a measure of the ACE activity. Determinations
were repeated at least 3 times to obtain activity values. The ACE activity
was also determined by using its endogenous substrate angiotensin I,
which is converted to angiotensin II by ACE (B). This reaction was
followed by HPLC. Area under the curve was calculated to quantify the
amount of the peptides. Calibration plots were constructed based on
standard concentrations of the peptides. Angiotensin I conversion was
followed by a kinetic assay, where angiotensin I and angiotensin II were
determined after 0, 2, 4 and 8 h. The slope of the linear fit gave the ACE
activity. A single representative experiment is illustrated (B). Parallel
experiments were performed to compare FAPGG and angiotensin I-
converting activities of the same sample (C). FAPGG converting
activities were plotted as a function of angiotensin I converting
activities. Plots were fitted by means of linear regression (solid line), the
symbols denote means 6 SEM of 3 independent determinations. The
goodness of fit (r2) is also indicated on figure.
doi:10.1371/journal.pone.0087843.g002
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and the retained sample were compared to evaluate the potential
loss (or enrichment) of ACE using a human ACE ELISA kit (R&D
Systems). No difference was found between the ACE concentra-
tion in the initial sample and in the retained fraction after filtration
(pore size: 100 kDa, ACE concentration: 119.5612.0 ng/mL,
n= 3 and 111.8611.0 ng/mL, n= 3, p = 0.459, respectively),
suggesting maintained concentrations of the proteins above the
pore size limit of the membranes.
Statistical analysis
Statistical analysis was performed with Graphpad Prism 5.0
software (GraphPad Software) by unpaired t-tests. Differences
were considered to be significant when p,0.05.
Results
Serum ACE activity was significantly affected by dilution
(Fig. 1A), increasing from 18.5 U/L at a 3-fold dilution to 51.4 U/
L at 32-fold dilution. In contrast, no such effects of dilution were
found on the purified tissue ACE activity (Fig. 1A). These data
suggest that ACE activity is modulated by additional factors
besides the ACE itself in the human serum. We hypothesized that
an endogenous reversible inhibitor is present in the human sera.
According to this hypothesis the endogenous reversible inhibitor
dissociates from the ACE at high dilutions, resulting in an
apparent increase in specific activity (Fig. 1B).
The cleavage of the artificial substrate N-[3-(2-furyl)acryloyl]-L-
phenylalanylglycylglycine (FAPGG, determined photometrically,
Fig. 2A) by human sera was compared with the conversion of the
physiological substrate angiotensin I (determined by HPLC,
Fig. 2B), in vitro, in separate sets of experiments. ACE activity
determined by FAPGG cleavage was directly proportional to
Figure 3. The size of the endogenous ACE inhibitor is in the range of 50–100 kDa. To determine the size of the endogenous ACE inhibitor,
serum samples were filtered through filter devices (50 kDa pore size, red; and 100 kDa pore size, blue; A). 1 volume of serum was diluted to 250
volume by the buffer and then ultrafiltration was done until 249 volume of the diluted sample has flown through the indicated pore size membranes,
yielding 1 volume of retained fraction (being the same as the volume of the initial serum sample). The ACE concentration was the same in the initial
serum sample and in the retained fraction, suggesting maintained protein concentrations in the case of the proteins with higher molecular sizes than
the pore size of the membranes (50 and 100 kDa). Both the initial sera and the retained fractions were diluted to the same extent to be able to
compare ACE activities. Since ACE concentration was the same in these samples at any dilutions, the effects of filtration is the consequence of the loss
of the inhibiting factors upon filtration. At least 4-fold dilution of the sera was necessary to measure ACE activity by FAPGG in the initial sera (high
level of absorbance at 340 nm by the human serum itself), therefore both the initial samples and the retained fractions were diluted to the same level
(4-fold) to compare the inhibited activities. Similarly, both samples were diluted to 32-fold to estimate the level of maximal ACE activity, when the
inhibitor was dissociated. Symbols denote means6 SD of 4 independent determinations. Significant differences from the unfiltered serum (green, A)
are indicated by asterisks. Serum ACE activities are also shown on the bar graph (B) at 4-fold dilution before (Control, green) and after filtering
through 50 kDa (red) and 100 kDa pore size (blue) devices. Unfiltered serum ACE activity is also shown at 32-fold dilution (Control, green). Bars
denote means 6 SEM of 4 independent determinations, significant differences are indicated by p values.
doi:10.1371/journal.pone.0087843.g003
Figure 4. Non-competitive ACE inhibition by the endogenous
serum factor. The reaction kinetics of FAPGG hydrolysis (in nmole/min
units) was determined at different FAPGG concentrations (750, 500, 250,
167 and 125 mM) to create a Lineweaver-Burk (double reciprocal) plot.
The same experiments were performed in the absence (vehicle) and
presence of captopril (50 nM) and the 50–100 kDa fraction of the
human serum (4.5-fold dilution). Symbols represent means 6 SEM of 3
independent determinations. Values were fitted by a linear regression.
doi:10.1371/journal.pone.0087843.g004
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angiotensin I to angiotensin II conversion (Fig. 2C), albeit FAPGG
cleavage was about 30-fold faster and easier to measure.
Efforts were made to prove the presence of the endogenous
inhibiting factor. Serum samples were filtered through ultrafilter
devices with different pore sizes. No effect was observed when
proteins with ,50 kDa molecular masses were removed, suggest-
ing that the inhibitor is above 50 kDa (.50 kDa, Fig. 3A). In
contrast, depletion of proteins with molecular masses ,100 kDa
from the human serum resulted in significantly elevated ACE
activities, without the apparent gradual increase in ACE activity
seen upon dilution in the original serum samples (fraction above
100 kDa, .100 kDa, Fig. 3A). In particular, the ACE activity
determined at the lowest (4-fold) dilution was ,2.2-fold higher in
serum depleted of proteins with molecular masses ,100 kDa
(increase in specific ACE activity from 26.460.7 U/L to
56.462.4 U/L, fraction .100 kDa, Fig. 3B). Moreover, serum
samples depleted from the endogenous inhibiting factor had
similar activities at 4-fold dilution than that for unfiltered serum
samples after dilution to 32-fold (at which conditions the
endogenous inhibitor is dissociated from the ACE, 56.462.4 U/
L, 67.561.8 U/L, respectively, Fig. 3B).
The type of inhibition was addressed next. ACE activity was
measured at constant inhibitor concentrations (serum fraction,
containing the endogenous inhibitor, 4.5-fold diluted compared to
the initial concentration of the 50–100 kDa components in the
human sera; captopril, an ACE inhibitory drug, 50 nM) using
different concentrations of the substrate (FAPGG, Fig. 4). A
Lineweaver-Burk plot was designed showing competitive ACE
inhibition by captopril (note similar y-axis intercepts in the cases of
vehicle and captopril), while the inhibition was found to be non-
competitive in the presence of the serum fraction (note similar x-
axis intercepts in cases of vehicle and endogenous serum inhibitor).
Captopril had higher efficacy than that is for 4-fold diluted
endogenous human serum inhibitor (50–100 kDa fraction) on
recombinant ACE catalyzing angiotensin I to angiotensin II
conversion measured by HPLC, while no inhibitory effect was
detected in the case of serum proteins below 50 kDa (,50 kDa,
Fig. 5A). The same was noted in FAPGG hydrolysis (Fig. 5B).
Moreover, inhibitory effect of captopril was not affected by
,50 kDa or 50–100 kDa serum fractions (Fig. 5B). Combination
of captopril and the endogenous serum inhibitor (50–100 kDa
fraction) resulted in higher ACE inhibition, than that is in the
absence of captopril (Fig. 5B).
Serum ACE has two catalytically active domains. Application of
specific fluorescent substrates for these active sites revealed that
captopril have the same potency and efficacy on both active sites
(Fig. 6A), while the endogenous serum inhibitor had higher
potency on the C-terminal active site than that is for the N-
terminal active site (Fig. 6B). Interestingly, the hydrolysis of the
fluorescent substrate Abz-FRK(Dnp)P-OH (non-specific for the
catalytic sites) was identical than that for the N-terminal site
specific substrate in this latter case.
Recombinant ACE was also inhibited by the endogenous serum
inhibitor (fraction 50–100 kDa) and captopril (Fig. 6C), when
measured by the Abz-FRK(Dnp)P-OH, similarly to the angioten-
sin I (Fig. 5A) and FAPGG hydrolysis (Fig. 5B), suggesting that the
ACE inhibition by the 50–100 kDa endogenous serum inhibitor is
not a substrate specific feature. On the other hand, the serum
fraction containing all of the components below 50 kDa (fraction
,50 kDa) was again without effects on recombinant ACE activity
on Abz-FRK(Dnp)P-OH hydrolysis, similarly to angiotensin I
(Fig. 5A) and FAPGG hydrolysis (Fig. 5B).
These data suggested that ACE is inhibited by a protein with an
apparent molecular mass of 50–100 kDa in human serum. It was
tested whether this inhibition is species dependent or an
evolutionary conserved general feature. Normal serum samples
from mouse, bovine, goat and donkey were tested and compared
to human. Serum ACE activities were significantly different in
these species ranging from 26.460.7 U/L in human to
157.2612.5 U/L in mouse at 4-fold dilution. Nonetheless, specific
ACE activities significantly increased upon dilution in each species
(by 2.8-fold, 1.8-fold, 1.5-fold, 1.7-fold and 2.6-fold, respectively,
Fig. 7).
The increase in specific ACE activity upon dilution was tested
under different assay conditions. Increase in specific activity was
present at physiological pH (Fig. 8A, increase in specific ACE
Figure 5. Efficacy of the ACE inhibition by human serum
fractions and captopril. Inhibition of recombinant ACE was
measured alone (vehicle) or in the presence of four-fold diluted human
serum fractions containing components below 50 kDa (,50 kDa), in
the range of 50–100 kDa and 1 mM captopril. Experiments were done
first using the physiological substrate angiotensin I (A). Bars represent
means 6 SD of 2 independent determinations, values are expressed in
the percentage of vehicle. The effects were also determined using the
artificial substrate FAPGG (B). In this latter case serum fractions were
also combined with captopril (,50 kDa+captopril and 50–100 kDa+-
captopril), in addition to the above mentioned conditions (,50 kDa,
50–100 kDa and 1 mM captopril). Bars represent means 6 SD of 3
independent determinations, values are given in the percentage of
vehicle, significant differences are indicated by p values.
doi:10.1371/journal.pone.0087843.g005
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activity by 1.89-fold at pH 7.4 versus 1.90-fold at pH 8.2) and
Cl2 concentrations (Cl2 is essential for ACE enzymatic activity,
Fig. 8B, increase in specific ACE activity by 1.46-fold at 105 mM
NaCl versus 1.39-fold at 300 mM NaCl). Increase in specific ACE
activity was not affected by the buffer concentration (Fig. 8C,
increase in specific ACE activity by 1.9-fold at 25 mM HEPES
versus 1.81-fold at 150 mM HEPES).
Finally, the specificity of FAPGG hydrolysis was also tested. A
set of protease inhibitors (Z-Prolyl-prolinal, prolyl-endopeptidase
inhibitor, 1 mM, Apstatin, aminopeptidase P inhibitor, 10 mM,
Amastatin, an inhibitor of various aminopeptidases, 10 mM,
Bestatin, leucin aminopeptidase and aminopeptidase B inhibitor,
1 mM, E-64, cysteine protease inhibitor, 1 mM, Leupeptin, serine
and cysteine protease inhibitor, 10 mM, PMSF, serine and cysteine
protease inhibitor, 100 mM, DX-600, ACE2 inhibitor, 1 mM) were
without effects on FAPGG conversion by human serum (Fig. 9).
On the other hand, captopril (an ACE inhibitor) successfully
inhibited FAPGG conversion (enzyme activity decreased from
37.660.4 (vehicle) to 0.960.4 U/L, Fig. 9).
Discussion
Here we propose that serum ACE is inhibited by an endogenous
inhibitor under physiological conditions. This endogenous inhib-
itor is a protein with an apparent molecular weight of 50–
100 kDa. Compared to competitive ACE-inhibitor drugs (like
captopril), the endogenous factor is a non-competitive inhibitor,
and it has higher potency on C-domain active site of ACE than N-
domain active site.
Endogenous ACE inhibition is particularly interesting in light of
the clinical effectiveness of ACE inhibitor drugs in cardiovascular
diseases [4–10], as evidenced by several large-scale trials, and as
accepted by the published guidelines [13–18]. Our data suggest
that ACE activity is suppressed by the endogenous inhibitor,
which may provide a protective mechanism for cardiovascular
disease. An important aspect of our findings is that the reversible
interaction between ACE and its inhibitor may provide a
mechanism capable of stabilizing serum ACE activities at different
levels of ACE concentration, similarly to conventional buffer
systems which can stabilize the pH. According to this analogy, if
the reversible inhibitor is in excess compared to ACE then the
ACE is in its inhibitor bound form, irrespectively of slight
variations in ACE concentration. Our data suggest that this
provide an evolutionary conserved mechanism for quenching
soluble ACE activity when it is shed from tissue sources, where it
fulfills its biological function.
Indeed, serum ACE concentration is under genetic control in
human. ACE insertion-deletion (I/D) polymorphism is responsible
for 20–50% of the interpersonal variability in circulating ACE
expression levels (II: 299.3649 mg/L, ID: 392.6667 mg/L, DD:
494.1688 mg/L) [30]. According to these substantial differences in
serum ACE activities it was proposed that the differences in ACE
expression (related to ACE I/D polymorphism) may play a role in
the occurrence of myocardial infarction, coronary artery disease,
coronary artery calcification, heart failure and hypertension.
However, most of the studies have failed to demonstrate any
association between these diseases and ACE I/D polymorphism
which is in accordance with our data [31].
One may argue that ACE I/D polymorphism determines not a
50% of blood ACE interpersonal variability as initially published
by Rigat in 1990, but only about 20% [32] [33] or even 8% [34].
Therefore it is not surprising that association of ACE DD genotype
with cardiovascular disease was not strong [35], in a sharp contrast
to ACE phenotype [36]. Motivated by these results the effect of
ACE I/D polymorphism on circulating ACE expression was tested
in our Hungarian population [31]. A substantial effect of genotype
was found on ACE expression (II: 101.066.7 mg/L, ID:
115.164.5 mg/L, DD: 157.766.3 mg/L), similarly to the original
report by Rigat et al., making this population a prime target for
further studies [31].
Irrespectively to the actual contribution of ACE genotype to
ACE activity, a meta-analysis of more than 30,000 individuals led
to the conclusion that ACE gene polymorphism does not affect
blood pressure, and is not associated with an increased risk of
myocardial infarction, ischemic heart disease or ischemic cere-
brovascular disease [35]. Important to note that ACE inhibitors
are primary used drugs to treat these diseases, suggesting a
substantial contribution of ACE to these diseases. Moreover, there
are mutations affecting more pronouncedly serum ACE concen-
tration than the ACE ID polymorphism. Kramers et al. reported
on cases involving a point mutation in the stalk region of the ACE
gene, in which the amount of circulating ACE was 5-fold elevated
[37]. This mutation affected at least eight families, but again, there
Figure 7. Endogenous serum ACE inhibition is evolutionary
conserved. Effects of dilution on serum ACE activity were tested in
different species. Specific ACE activities were plotted as a function of
dilution levels. Symbols denote means 6 SEM of at least 3 independent
determinations. Significant differences from ACE activity values
measured at 4-fold dilution are indicated by asterisks.
doi:10.1371/journal.pone.0087843.g007
Figure 6. The endogenous ACE inhibitor has higher affinity at the C-terminal active site of ACE. Inhibition of serum ACE was tested by
active site specific flourescent substrates: (Abz-SDK(Dnp)P-OH (triangles) for the N-terminal active site, Abz-LFK(Dnp)-OH (squares) for the C-terminal
active site). Abz-FRK(Dnp)P-OH (circles) was used as non-site specific substrate. Captopril (0.01 nM–100 nM, A) concentration-dependently inhibited
serum ACE activity determined by all three substrates with a similar affinity. In contrast, serum fraction containing 50–100 kDa components (0.02–
20 mg/mL protein concentration, 20 mg/mL represents 2.34-fold dilution, B) had higher affinity at the C-terminal active site (determined by Abz-
LFK(Dnp)-OH). Symbols represent means 6 SEM of 3 independent determinations, values are given in the percentage of control (without ACE
inhibitor). Inhibitory activity of the serum fractions (proteins below 50 kDa, or in the range of 50–100 kDa, 2-fold dilution) and captopril (1 mM) were
selectively tested by the Abz-FRK(Dnp)P-OH substrate (non-site specific flourescent substrate, C). Bars represent means 6 SEM of the recombinant
ACE activities in the percentage of vehicle (n = 3).
doi:10.1371/journal.pone.0087843.g006
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were no ACE-related clinical abnormalities or hypertension.
Nesterovitch et al. described another mutation that was accom-
panied by a 13-fold elevation of the serum ACE concentration,
which again did not result in any disease [38]. All of these
observations suggest that substantial differences in ACE concen-
trations are well tolerated. This may be explained by the presence
of the reversible inhibitor stabilizing (buffering) ACE activity, in
vivo, reported here.
An alternative explanation is that tissue level of ACE is 10–30
fold more than blood ACE, therefore tissue ACE participate more
in cleavage of vasoactive peptides and even such increase in blood
ACE do not contribute significantly in overall peptide hydrolysis
by ACE [39]. However, we would like to point out that most of the
data related to ACE ‘‘level’’ was determined by measuring ACE
activity, instead of ACE concentration. Our data suggest that there
may not be a direct relationship between ACE activity and
expression. In particular, the endogenous inhibitor shown here
may mask ACE activity in the serum, while it may not be present
in the isolated tissues, resulting in high apparent ACE ‘‘levels’’ in
the tissues and low apparent ACE ‘‘levels’’ in the serum. ACE
‘‘levels’’ may represent simply those ACE pools, where ACE is not
inhibited effectively, under the conditions used to isolate ACE.
As a matter of fact one of the implications of this study is that
ACE activity is controlled by endogenous inhibitors. Circulating
ACE may be suppressed, irrespectively to its concentration. In this
Figure 8. Differences in pH, ionic strength and buffer
concentration do not effect the increase in ACE activities upon
dilution. Effects of dilution (4 and 20-fold) were tested on ACE activity
under different assay conditions. Increase in specific ACE activity was
present at physiological pH (A), at physiological Cl2 (B) and at higher
buffer concentrations (C). Blue bars represent optimal assay conditions
used in the previous experiments. Bars denote means 6 SEM of at least
3 determinations. Significant differences are indicated by the p values.
The increase in ACE activities for each pairs are also shown within the
bars.
doi:10.1371/journal.pone.0087843.g008
Figure 9. Effects of various protease inhibitors on FAPGG
hydrolysis by human serum. Human serum (8-fold dilution) was
incubated with Z-Prolyl-prolinal (prolyl-endopeptidase inhibitor, 1 mM),
Apstatin (aminopeptidase P inhibitor, 10 mM), Amastatin (an inhibitor of
various aminopeptidases, 10 mM), Bestatin (leucin aminopeptidase and
aminopeptidase B inhibitor, 1 mM), E-64 (cysteine protease inhibitor,
1 mM), Leupeptin (serine and cysteine protease inhibitor, 10 mM), PMSF
(serine and cysteine protease inhibitor, 100 mM), DX-600 (ACE2
inhibitor, 1 mM) and captopril (an ACE inhibitor, 1 mM) for 15 min.
ACE activity measurement was initiated by the addition of FAPGG.
Enzyme activity was measured for 120 min and apparent enzyme
activities were expressed and plotted in absolute (U/L) units. Bars
represent mean 6 SEM of three independent determinations.
Significant difference (p,0.001) from the control (vehicle) is indicated
by the asterisk.
doi:10.1371/journal.pone.0087843.g009
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respect, circulating ACE may be a pool of inactivated ACE. One
may speculate that the evolutionary function of the endogenous
ACE inhibition is to neutralize ACE when it is shed from the
tissue, to make sure that it does not interfere with its physiological
function in the tissues. To validate these implications new human
trials are necessary. In particular, we have proven that the
endogenous inhibition in the sera shown here can suppress
differences in ACE concentrations, such as reported in relation to
the ACE genotype [31].
Regarding the existence of endogenous ACE inhibiting factors
there are some important earlier reports in the literature.
Existence of endogenous ACE (called kininase II at this time)
inhibitors were proposed as early as 1979. Klauser et al. reported
that plasma preparations and human serum albumin inhibit the
ACE [20], which was also confirmed by us [40] while Ryan et al.
reported that small (,10 kDa) molecular weight components of
human sera and urine are also able to inhibit purified ACE [21].
These original reports were followed by some reports suggesting
that substrate analogues (such as angiotensin I [22] and substance
P [23]) can also inhibit ACE. The existence of endogenous ACE
inhibitors were confirmed later. Lieberman et al. reported an ACE
inhibitor with an apparent molecular mass of .50 kDa [24].
Ikemoto et al. reported the presence of an other sulfhydryl (SH)
specific endogenous inhibitor, with an apparent molecular mass of
.10 kDa [25]. C-type natriuretic peptide was also proposed to
have indirect inhibitory effects on ACE activity, although the exact
mechanisms were not revealed [41]. Identification of the synthetic
ACE inhibitors as a new class of drugs acting on blood pressure
[42] gave rise to the technique which made it possible to affinity
purify ACE (captopril or lisinopril affinity chromatography),
together with its interaction partners. It was revealed that ACE
associates with both low and high molecular weight ACE
inhibitors in the rat lung [26] or with a 14 kDa inhibiting protein
in the human sera [27]. The clinical success of the synthesized
ACE inhibitors also facilitated the identification of dietary factors
with ACE inhibiting properties, such as peptides of the tryptic
lisate of human plasma [43,44], human serum albumin [45],
bovine alphaS2-casein [46]. Some of the beneficial effects of honey
were also related to ACE inhibitory activities [47].
Our data do not support the existence of low molecular weight
ACE inhibitors in the sera. Serum fractions containing compo-
nents under 50 kDa did not show any inhibitory effects on serum
or recombinant ACE activity. The possible explanation can be the
connection of these inhibitors to diet. Blood sample collections
were executed after overnight fasting period of the healthy
volunteers, which probably enabled the elimination of low
molecular weight inhibitors from the circulation. It is also possible
that some of these small molecular weight inhibitors are the result
of proteolytic degradation of the high molecular weight inhibitor(s)
and that this proteolysis did not occur in our samples. Finally, it is
also possible that we have used to high dilution factors to detect
these small molecular weight regulators of human circulating
ACE.
These findings suggest that the determination of ACE activities
can be complicated by the endogenous inhibitor. Indeed, an
earlier work suggested an 8-fold dilution to get rid of the inhibitory
effect in ACE activity measurements [24]. Dilution may be a good
technique to eliminate the effects of endogenous inhibitors to
obtain reliable ACE activity values, but it may cause some
confusion in the interpretation of the data. In particular,
Figure 10. Hypothetical function of the endogenous angiotensin converting enzyme (ACE) inhibitor. The clinical success of ACE
inhibitory drugs prove that ACE is a physiologically important angiotensin I converting enzyme. Here we propose the existence of an endogenous
ACE inhibitor in human sera (Inh) which provide an evolutionary conserved mechanism for the suppression of circulating ACE activity. We
hypothesize that ACE is catalytically active in the tissues, where it converts angiotensin I to angiotensin II. The formed angiotensin II then binds to its
resident receptors (ATR) and activates intracellular signal transduction leading to physiological responses. Soluble ACE is the result of the shedding of
tissue-bound ACE mediated by the ACE secretase (S). Our data suggest that this soluble ACE activity is inhibited by an endogenous inhibitor (Inh),
restricting ACE mediated angiotensin I conversion to the tissues, irrespectively to the concentration of the circulating ACE. ACE function appears to
be quenched by the endogenous inhibitor when it is secreted into the systemic circulation. This mechanism may contribute to the confinement of
angiontensin II mediated physiological responses.
doi:10.1371/journal.pone.0087843.g010
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physiological ACE activity may be significantly overestimated. We
have demonstrated here that physiological ACE activities are at
least 2.8-fold overestimated when in vitro determination is done at
high dilutions. Note, that this value (2.8-fold overestimation)
represents the minimum factor by which ACE is physiologically
inhibited. Indeed, it has been proven in accompanying papers that
physiological ACE activity is much lower than one third of the
measured ACE activity [31,40].
Our findings suggest that this endogenous inhibitor has a
relatively low dissociation constant, because its effect can be easily
eliminated using low dilutions of serum samples. Thus the isolation
of this inhibitor is a great challenge, considering it will be lost
during washing steps of purification.
The main novel information in the current study is: (1) FAPGG
and angiotensin I conversions are closely related, and therefore the
endogenous inhibition is probably not an artifact resulting from
the use of the artificial substrate; (2) The increase in ACE activity
by dilution is not present when ACE is recombinantly expressed;
(3) Endogenous inhibition of ACE is an evolutionary conserved
mechanism; (4) The endogenous ACE inhibition is non-compet-
itive; (5) The endogenous ACE inhibitor has a higher affinity on
the C-terminal active site of the ACE.
Based on these findings we propose that the activity of
circulating ACE, shedded into the serum, is inhibited by an
endogenous inhibitor providing an evolutionary conserved mech-
anism for suppressing circulating ACE activity (Fig. 10).
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